Reuters was ahead of competitors with news that Eli Lilly’s unscheduled trading update revealed lower-than-expected fourth-quarter sales of the weight-loss drug Zepbound, causing the drugmaker’s shares to drop by 8%. This development had a significant impact on the market, highlighting the importance of timely and accurate information in the business and finance sector.
Full Article
This Monster Artificial Intelligence (AI) Data Center Stock Is the Real Winner From Google's Deal with OpenAI (Hint: It's Not Nvidia)
Nvidia, Palantir Technologies, and Tesla often dominate AI headlines, but OpenAI, the pioneer of the AI revolution, is making waves with its recent partnership with Alphabet. This collaboration is significant and could reshape the AI landscape, emphasizing OpenAI's pivotal role in the industry. Need More Context? 🔎
Read more